Cytek Biosciences, Inc. (CTKB) Reports In-Line Q2 EPS ; Offers Guidance

Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q2 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $45.6 million versus the consensus estimate of $46.03 million.

GUIDANCE:

Cytek Biosciences, Inc. sees FY2025 revenue of $196-205 million, versus the consensus of $197.9 million.

For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.

You May Also Be Interested In

• China semiconductor equipment imports grow 9% in July, Barclays comments
• Advance Auto Parts falls on revenue miss, weak guidance
• UBS Reiterates Buy Rating on Dutch Bros Inc. (BROS): 'One of Strongest Growth Stories in Restaurants'